anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this study, a before-and-after type of quasi-experimental study will be conducted in purposely selected health centers Sidama region, Ethiopia. base line assessment of postpartum contraceptive utilization rate will be done which will be followed by an intervention. The intervention consists of screening, counseling for family planning and referring mothers coming for infant immunization services to family planning units. All mothers coming for infant immunization service will be screened for and counseled for family planning and those who will be voluntary to take any method will be referred to family planning unit. All mothers who will not be voluntary will be re-counseled by the next visit.

Finally, the effect of this intervention on postpartum contraceptive utilization rate will be reassessed. The expected outcome will be to see an improved contraceptive uptake during the first year after delivery.
Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
Patients enrolled in the study group will receive a PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone. The block will be performed with the patient in a supine position using an 18-gauge, 90 mm needle, inserted with an in-plane lateral to medial approach. Operators will use the original technique described by Girón-Arango L et al. The aim of this block is to inject the local anaesthetic between the psoas tendon and the iliopubic eminence. We will instruct operators to routinely use a curvilinear probe (2-6 MHz) or a linear probe (4-16 MHz) in particularly lean or cachectic patients.
VIRAMUNE is the brand name for nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Nevirapine is structurally a member of the dipyridodiazepinone chemical class of compounds.

The chemical name of nevirapine is 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e][1,4] diazepin-6-one. Nevirapine is a white to off-white crystalline powder with the molecular weight of 266.30 and the molecular formula C15H14N4O. Nevirapine has the following structural formula:

VIRAMUNE is for oral administration. Each 5 mL of VIRAMUNE oral suspension contains 50 mg of nevirapine (as nevirapine hemihydrate). The suspension also contains the following inactive ingredients: carbomer 934P, methylparaben, polysorbate 80, propylparaben, purified water, sodium hydroxide, sorbitol, and sucrose.
Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy, whether that use is medically-authorized or illicit. Unlike opioid withdrawal syndrome in adults, NOWS may be life-threatening if not recognized and treated in the neonate. Healthcare professionals should observe newborns for signs of NOWS and manage accordingly [see Use in Specific Populations (8.1)]. 

Advise pregnant women receiving opioid addiction treatment with buprenorphine sublingual tablets of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations (8.1)]. This risk must be balanced against the risk of untreated opioid addiction which often results in continued or relapsing illicit opioid use and is associated with poor pregnancy outcomes. Therefore, prescribers should discuss the importance and benefits of management of opioid addiction throughout pregnancy.
PURPOSE OF REVIEW: As compared to controlled or uncontrolled hypertension, resistant hypertension in patients with chronic kidney disease (CKD) poses a significantly increased healthcare burden due to greater target end-organ damage including cardiovascular disease and CKD progression. Patients with CKD have two to three times higher risk of developing resistant hypertension. True resistant hypertension needs to be distinguished from apparent treatment resistant hypertension (aTRH); however, it is usually not possible in epidemiological studies. Moreover, impact of contemporary guidelines changes in the target blood pressure (BP) goal to less than 130/80 mmHg remains to be determined.
RECENT FINDINGS: Up to half of patients with CKD meet aTRH criteria using 2017 ACC/AHA target BP less than 130/80 mmHg. Excess sodium retention in extracellular and tissue compartment remains the cornerstone cause of resistance to the treatment in CKD. Maximizing and optimizing the diuretic regimen in addition to dietary sodium restriction plays a critical role in these patients. Management requires a trustworthy provider-patient relationship facilitating identification and intervention for the barriers restricting the uptake of lifestyle modifications and medications. Recently, renal denervation has been approved and many other novel agents are on the horizon for treatment of true resistant hypertension associated with CKD.
SUMMARY: This review discusses the latest in the pathophysiology, definition, identification and treatment strategies of resistant hypertension in individuals with CKD. Further investigations are required to identify the prevalence, future implication and treatment outcome data for true resistant hypertension associated with CKD.
In various example embodiments, a system and method for facilitating proximity detection and location tracking using a mobile wireless bridge are provided. The system includes a beacon badge, a beacon tag, and a real-time location services ("RTLS") server communicatively coupled to the beacon badge, such as via a wireless network or the like. The beacon tag broadcasts a beacon message receivable by the beacon badge. The beacon badge determines whether it is proximate to the beacon badge based on the signal strength of the received beacon message. The beacon badge further communicates identifying information contained with the received beacon message to the RTLS server. The RTLS server uses the identifying information to determine the proximate location of the beacon badge.
The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
BACKGROUND: Cerebral Palsy (CP) is a major cause of motor and cognitive disability in children due to injury to the developing brain. Early intensive sensorimotor rehabilitation has been shown to change brain structure and reduce CP symptoms severity. We combined environmental enrichment (EE) and treadmill training (TT) to observe the effects of a one-week program of sensorimotor stimulation (EETT) in animals exposed to a CP model and explored possible mechanisms involved in the functional recovery.
METHODS: Pregnant Wistar rats were injected with Lipopolysaccharide (LPS - 200 µg/kg) intraperitoneally at embryonic days 18 and 19. At P0, pups of both sexes were exposed to 20' anoxia at 37 °C. From P2 to P21, hindlimbs were restricted for 16 h/day during the dark cycle. EETT lasted from P21 to P27. TT - 15 min/day at 7 cm/s. EE - 7 days in enriched cages with sensorimotor stimulus. Functional 3D kinematic gait analysis and locomotion were analyzed. At P28, brains were collected for ex-vivo MRI and histological assessment. Neurotrophins and key proteins involved in CNS function were assessed by western blotting.
RESULTS: CP model caused gross and skilled locomotor disruption and altered CNS neurochemistry. EETT reversed locomotor dysfunction with minor effects over gait kinematics. EETT also decreased brain inflammation and glial activation, preserved myelination, upregulated BDNF signaling and modulated the expression of proteins involved in excitatory synaptic function in the brain and spinal cord.
CONCLUSIONS: Using this translational approach based on intensive sensorimotor rehabilitation, we highlight pathways engaged in the early developmental processes improving neurological recovery observed in CP.
RELYVRIO contains two active ingredients: sodium phenylbutyrate and taurursodiol. 

The chemical designation for phenylbutyrate is 4-phenyl butyric acid sodium salt. Its molecular formula is C10H11NaO2, and its molecular weight is 186.2. The sodium phenylbutyrate chemical structure is:

Sodium phenylbutyrate is a white or yellow powder which decomposes at about 220°C. It is freely soluble in water and methanol; sparingly soluble in ethanol; and practically insoluble in methylene chloride, acetone, and diethyl ether.

Taurursodiol, also known as tauroursdeoxycholic acid, is an ambiphilic bile acid and is the taurine conjugate of ursodiol, also known as ursodeoxycholic acid. The chemical name of taurursodiol is 2-[(3α, 7β-dihydroxy-24-oxo-5β-cholan-24-yl) amino] ethane sulfonic acid, dihydrate. The molecular formula is C26H45NO6S . 2H2O and the molecular weight is 535.74 (dihydrate).

The taurursodiol chemical structure is:

Taurursodiol is a white microcrystalline powder, practically odorless, with a bitter taste. It is freely soluble in ethyl alcohol, very slightly soluble in acetone and dioxane, sparingly soluble in water, and practically insoluble in ether and ethyl acetate.

RELYVRIO is a white to yellow powder for oral suspension that consists of fine to large granules. RELYVRIO is supplied in a packet containing 3 g sodium phenylbutyrate (equivalent to 2630 mg phenylbutyrate) and 1 g taurursodiol. Each packet contains 464 mg of sodium and also contains the following inactive ingredients: acacia, dextrates, dibasic sodium phosphate, maltodextrin, medium-chain triglycerides, mixed berry flavoring, other flavoring ingredients, silicon dioxide, sodium stearyl fumarate, sorbitol, and sucralose.
Fibrovein 3% foamed with air 50/ 50. Total volum injected is the same as volume of malfomation. Volume of malformation estimated by contrast media injection before sclerotherapy.
FIELD: pharmacology, complex natural compounds. SUBSTANCE: suspension consisting of 1 mas. p. arginine and 2-4 mas. p. hyaluronic acid in 40-50 mas. p. water is heated at 80-90 C for 1-2 hr. Solution is cooled to 4-6 C, 4-6 volumes of ethanol were added, precipitate is separated, washed repeatedly with ethanol and dried in the air. Obtained complex administrated in blood stream of warm-blooded animal at a single small dose causes prolonged decrease of blood cholesterol. Complex can be used for prophylaxis and treatment of atherosclerosis and related diseases. EFFECT: enhanced effectiveness of complex
Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
Tab-G participants will receive 4 weekly CBT(cognitive behavioral therapy)-based group learning sessions to encourage a simple walking activity through videoconferencing meetings in a group of 5 members. The educational materials emphasize shared goal setting and mutual reinforcement.
The presently claimed invention applies to a genetic material processing and manipulation method and related product. The claimed invention relates to a method for changing the inherited characteristics of a cell through micro-beam chromosome modification. In one preferred embodiment, improvements to ‘genomic surgery’ are applied to modify source cell genetic material ( 101 ). Source cell ( 106 ) is stabilized through micro-pipette ( 102 ) applied negative pressure. Excised genetic material ( 101 ) undergoes a pre-cutting manipulation step ( 205 ) to enhance subsequent genetic manipulation. In an additional embodiment genetic material manipulation is aided by a spindle cutting step ( 303 ). The presently claimed invention provides a high quality alternate approach to directed genetic recombination without requiring the use of restriction enzymes and is used for chromosomal repair, removal of defects and new organism creation.
Sexually transmitted diseases (STDs), including HIV infections, are most commonly spread through unprotected sexual intercourse. STDs are a primary health issue, especially among young ethnic minorities in the United States. The rate of STDs is significantly greater in urban areas where ethnic minorities, particularly African-American males, are commonly represented. Despite this information, safe sexual practices, including correct condom use, are not commonly followed among minority males. It is believed that educational outreach designed to motivate and inform on the correct use of condoms will be effective in encouraging safer sex practices. A cell phone-based text messaging program designed to promote safer sex practices may provide an effective and easy means of delivery of treatment. This study will develop and test the effectiveness of a cell phone-based text messaging program to sustain abstinence, monogamy, or condom use among black urban males in Philadelphia, Pennsylvania.

Participation in this study will be divided into two phases. In the first study phase, participants will partake in a 90-minute focus group to help develop text message content and plans for treatment delivery. The next study phase will be a pilot test of the program developed in the first phase. Participants will be assigned to receive text messages concerning either HIV prevention or general nutrition. Participants receiving the HIV prevention text messages will be sent up to 90 text messages related to abstinence, monogamy, and condom use over a 3-month period. Participants will also be able to join interactive phone activities related to HIV. Participants receiving the nutritional text messages will be sent up to 30 messages about nutrition and healthy eating over the same period of time. Participants will complete telephone surveys at baseline and Months 3 and 6. The surveys will assess measures of abstinence, monogamy and condom use attitudes, norms, self-efficacy, and risk behaviors.
Subacute sclerosing panencephalitis (SSPE) is a rare but fatal late neurological complication of measles, caused by persistent measles virus (MeV) infection of the central nervous system. There are no drugs approved for the treatment of SSPE. Here, we followed the clinical progression of a 5-year-old SSPE patient after treatment with the nucleoside analog remdesivir, conducted a post-mortem evaluation of the patient's brain, and characterized the MeV detected in the brain. The quality of life of the patient transiently improved after the first two courses of remdesivir, but a third course had no further clinical effect, and the patient eventually succumbed to his condition. Post-mortem evaluation of the brain displayed histopathological changes including loss of neurons and demyelination paired with abundant presence of MeV RNA-positive cells throughout the brain. Next-generation sequencing of RNA isolated from the brain revealed a complete MeV genome with mutations that are typically detected in SSPE, characterized by a hypermutated M gene. Additional mutations were detected in the polymerase (L) gene, which were not associated with resistance to remdesivir. Functional characterization showed that mutations in the F gene led to a hyperfusogenic phenotype predominantly mediated by N465I. Additionally, recombinant wild-type-based MeV with the SSPE-F gene or the F gene with the N465I mutation was no longer lymphotropic but instead efficiently disseminated in neural cultures. Altogether, this case encourages further investigation of remdesivir as a potential treatment of SSPE and highlights the necessity to functionally understand SSPE-causing MeV.IMPORTANCEMeasles virus (MeV) causes acute, systemic disease and remains an important cause of morbidity and mortality in humans. Despite the lack of known entry receptors in the brain, MeV can persistently infect the brain causing the rare but fatal neurological disorder subacute sclerosing panencephalitis (SSPE). SSPE-causing MeVs are characterized by a hypermutated genome and a hyperfusogenic F protein that facilitates the rapid spread of MeV throughout the brain. No treatment against SSPE is available, but the nucleoside analog remdesivir was recently demonstrated to be effective against MeV in vitro. We show that treatment of an SSPE patient with remdesivir led to transient clinical improvement and did not induce viral escape mutants, encouraging the future use of remdesivir in SSPE patients. Functional characterization of the viral proteins sheds light on the shared properties of SSPE-causing MeVs and further contributes to understanding how those viruses cause disease.
The invention provides a traditional Chinese medicine for treating enteritis. The traditional Chinese medicine consists of thirteen medicines as follows: the root of kudzu vine, Scutellaria baicalensis, Coptis chinensis, radix paeoniae alba, elecampane, radices sileris, roasted Rhizoma Atractylodis Macrocephalae, poria, fructus aurantii, rattletop, pericarpium citri reticulatae, liquorice and Chinese-dates. The preparation method comprises the following steps: weighing the raw materials in parts by weight; soaking the raw materials for 1-1.5 hours, wherein the level of cold water is higher than the raw materials; boiling by strong fire, decocting for 25-35 minutes by soft fire, and filtering to remove dregs to obtain a medicine liquid; and decocting twice, mixing the two medicine liquids, and boiling the mixture for 4-5 minutes by soft fire to obtain the traditional Chinese medicine. The effective components of the thirteen medicines provided by the invention are assimilated by a human body to accelerate blood circulation of the intestinal tract and repair damaged intestinal histocytes so as to reach the treatment purpose. The medicine provided by the invention is characterized in that the traditional Chinese medicine not only has the functions of clearing away heat and toxic materials, eliminating swelling, relieving pains and promoting blood circulation to remove blood stasis, but also can reduce the toxicity and adverse effects of the medicinal raw materials. The traditional Chinese medicine treats internal illnesses by external treatment, treats both symptoms and root causes and consolidates the basis, so as to reaching the purpose of comprehensively adjusting and repairing various physiological functions of the intestinal tract.
Provided is a chimaeric protein comprising a ubiquitin ligase domain and a RAS-specific endogenous targeting portion. The ubiquitin ligase domain may be a VHL E3 ligase domain, or a fragment or variant thereof having ubiquitin ligase activity; or a UBOX domain of CHIP, or a fragment or variant thereof having ubiquitin ligase activity. The RAS-specific endogenous targeting portion may be a RAS-specific DARPin; or a RAS-specific intracellular antibody. In particular, the RAS-specific endogenous targeting portion may be a KRAS-specific endogenous targeting portion (for example a KRAS-specific DARPin, or a KRAS-specific intracellular antibody). The chimaeric proteins may be used in the prevention and/or treatment of a RAS-associated disorder, such as a RAS-associated cancer or a RASopathy. Further provided is a chimaeric protein comprising a ubiquitin ligase domain and an LMO2-specific endogenous targeting portion.
AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
BACKGROUND: Frailty is multifactorial; however, psychosocial stressors contributing to frailty are poorly understood. This study aimed to examine whether gender, race/ ethnicity, and education are associated with differential exposure to psychosocial stressors, determine psychosocial stressors contributing to frailty, and explore the mediating psychosocial stressors pathway.
METHODS: This cross-sectional study involved 7679 community-dwelling older adults (≥65) from the Health and Retirement Study (2006 and 2008 waves). Psychosocial stressors such as loneliness, low subjective social status, financial strain, poor neighborhood cohesion, everyday discrimination, and traumatic life events were measured. Frailty was defined by the Fried phenotype measure. Multivariable logistic regressions were used to examine the association of gender, race/ethnicity, and education with psychosocial stressors, psychosocial stressors associated with frailty, and the mediating psychosocial stressors pathway.
RESULTS: Females experienced greater financial strain but lower discrimination (both p < 0.05). Older adults who identified as Hispanic, Black, and racially or ethnically minoritized experienced low subjective social status, high financial strain, low neighborhood cohesion, and high discrimination than their White counterparts (all p < 0.05). Those with lower education experienced high loneliness, low subjective social status, high financial strain, low neighborhood cohesion but lower traumatic life events (all p < 0.05). Psychosocial stressors: High loneliness, low subjective social status, high financial strain, and low neighborhood cohesion (all p < 0.05) independently increased the odds of frailty. The mediating pathway of psychosocial stressors was not significant.  CONCLUSION: Disparities exist in exposure to psychosocial stressors associated with frailty. Multilevel interventions are needed to reduce the influence of psychosocial stressors on frailty.
The reversal of liver fibrosis requires effective strategies to reduce oxidative stress and inhibition of hepatic stellate cell (HSC) activation. MiR-4500 regulates pathological angiogenesis and collagen mRNA stability, with the potential to inhibit fibrosis. Herein, we explored the inhibition of HSC activation in vitro by exosomes (Exos) carrying miR-4500 and encapsulated ExosmiR-4500 in an intelligent injectable hydrogel with biological activity and reactive oxygen species (ROS) responsiveness for application in oxidative stress environments. Briefly, reversible boronic ester bonds were integrated into gelatin-based hydrogels through dynamic crosslinking of quaternized chitosan (QCS) and 4-carboxyphenylboronic acid (CPBA)-modified gelatin. The QCS-CPBA-Gelatin (QCG) hydrogel scavenged excess ROS from the local microenvironment and released ExosmiR-4500 through the dissociation of boronic ester bonds, providing a favorable microenvironment and in situ sustained-release drug delivery system for ExosmiR-4500. The results showed that QCG@ExosmiR-4500 hydrogel has biocompatibility, biodegradability, and slow-release ability, which could effectively clear ROS and inhibit HSC activation and pathological angiogenesis in vitro and in vivo. Furthermore, transcriptome analysis suggests that the pharmacological mechanism of the QCG@ExosmiR-4500 hydrogel is mainly related to anti-oxidation, anti-angiogenesis, anti-fibrosis processes, and signaling pathways. Thus, our study demonstrates that an intelligently responsive ExosmiR-4500 delivery system based on injectable hydrogels is a promising strategy for the treatment of liver fibrosis.